Page 8 - Double Blind Study News Today

The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.

The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.

Obgemsa is suitable for treating symptoms of an overactive bladder in adults, the European Medicines Agency has determined.

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Pz-cel, which comprises autologous, COL7A1 gene–corrected epidermal sheets, was designed to enable normal type VII collagen expression and facilitate wound healing and pain reduction in RDEB wounds.

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

Growing evidence suggests invasive procedures may not be needed to confirm a celiac disease diagnosis.

Expect intradermal injections of botulinum toxin A for the improvement in the appearance of pores, sebum, skin texture, and rosacea to gain a foothold in dermatology practices, one expert says.

The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.

Semaglutide is an effective treatment option for weight loss, but its cost-effectiveness over the long term compared with ESG needs to be considered.